Mads Daugaard

Presidente presso RAKOVINA THERAPEUTICS INC.

Finance

Consumer Services

Commercial Services

Profilo

Mads Daugaard is the founder of VarCT Diagnostics ApS, founded in 2017, and Var2 Pharmaceutical, founded in 2012, where the title held is Chairman.
Current jobs include Chairman at Oncomal ApS, Associate Professor at the University of British Columbia, and President & Chief Scientific Officer at Rakovina Therapeutics, Inc. since 2021.
Former job includes Head-Molecular Pathology & Cell Imaging Unit at The Vancouver Prostate Centre.

Posizioni attive di Mads Daugaard

Società	Posizione	Inizio
RAKOVINA THERAPEUTICS INC.	Presidente	01/01/2021
University of British Columbia University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	-
Var2 Pharmaceutical	Fondatore	01/01/2012
VarCT Diagnostics ApS VarCT Diagnostics ApS VarCT Diagnostics ApS specializes in developing in vitro diagnostic assays for cancer detection and monitoring, focusing on the oncofetal chondroitin sulfate (ofcs) biomarker, which is re-expressed in most cancers but largely absent from healthy tissues except the placenta. The private company is based in Copenhagen, Denmark. The Danish company utilizes recombinant var2csa protein and proprietary high-affinity antibodies called vartumabs to detect ofcs with high sensitivity and specificity. The company's assays support early cancer detection, residual disease monitoring, and multi-cancer screening, including colorectal and bladder cancers, and they are developing immunohistochemistry companion diagnostics for tumor biopsies. VarCT Diagnostics is also advancing therapeutic applications using vartumabs-based platforms and plans a phase 0 microdosing clinical trial in 2024. The company maintains strategic collaborations with academic and industry partners internationally. The company was founded by Mads Daugaard.	Fondatore	01/01/2017
Oncomal ApS Oncomal ApS Financial ConglomeratesFinance Functions as a financial holding company	Presidente	-

Tutte le posizioni attive di Mads Daugaard

Precedenti posizioni note di Mads Daugaard

Società	Posizione	Fine
The Vancouver Prostate Centre The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services Provides prostate cancer research, treatment, and education services	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Mads Daugaard

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Vedi nel dettaglio l'esperienza di Mads Daugaard

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	6
University of British Columbia University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The Vancouver Prostate Centre The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services Provides prostate cancer research, treatment, and education services	Commercial Services
Rakovina Therapeutics, Inc. Rakovina Therapeutics, Inc. Financial ConglomeratesFinance Develops oncology therapeutics	Finance
Var2 Pharmaceutical
Oncomal ApS Oncomal ApS Financial ConglomeratesFinance Functions as a financial holding company	Finance
VarCT Diagnostics ApS VarCT Diagnostics ApS VarCT Diagnostics ApS specializes in developing in vitro diagnostic assays for cancer detection and monitoring, focusing on the oncofetal chondroitin sulfate (ofcs) biomarker, which is re-expressed in most cancers but largely absent from healthy tissues except the placenta. The private company is based in Copenhagen, Denmark. The Danish company utilizes recombinant var2csa protein and proprietary high-affinity antibodies called vartumabs to detect ofcs with high sensitivity and specificity. The company's assays support early cancer detection, residual disease monitoring, and multi-cancer screening, including colorectal and bladder cancers, and they are developing immunohistochemistry companion diagnostics for tumor biopsies. VarCT Diagnostics is also advancing therapeutic applications using vartumabs-based platforms and plans a phase 0 microdosing clinical trial in 2024. The company maintains strategic collaborations with academic and industry partners internationally. The company was founded by Mads Daugaard.